Protocol Ledger

NCT06447597 · Phase II/III · RECRUITING

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Interventional Phase II/III clinical trial protocol NCT06447597 sponsored by Shanghai Jiaolian Drug Research and Development Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-01 Enrollment: 104 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06447597
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)104 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06447597
Protocol FieldVerified Registry Value
NCT IdentifierNCT06447597
Consolidated Lead SponsorShanghai Jiaolian Drug Research and Development Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment104 participants (ESTIMATED)
Registered Start Date2024-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI